Upsc
Upsc
Upsc
This editorial is based on “ Biotech enigma: On the BioE3 proposal and beyond” which was published in
The Hindu on 30/08/2024. The article highlights the recent BioE3 policy as a significant initiative to boost
India's biotechnology sector but emphasizes that its success hinges on sustained financial support and
collaboration between central and state governments.
For Prelims: Biotechnology sector, Vaccine development, Climate-resilient Agriculture, Carbon capture,
Biopharmaceuticals, Biotech-KISAN, Union Budget 2023-24, GenomeIndia Project, Diphtheria, Tetanus and
Pertussis, Bt cotton, Golden rice, Active pharmaceutical ingredients, Biofuels.
For Mains: Current Status of India’s Biotechnology Sector, Significance of Biotechnology for India, Key
Challenges Hindering the Growth of Biotechnology in India.
India's Cabinet has approved the BioE3 (Biotechnology for Economy, Environment and
Employment) proposal to boost manufacturing in the biotechnology sector. While India has made
significant strides in areas like vaccine development, the country has yet to fully capitalize on the
broader potential of biotechnology. The BioE3 policy focuses on six verticals, including bio-based
chemicals, functional foods, precision biotherapeutics, climate-resilient agriculture, carbon capture,
and marine/space research. While well-intentioned, the policy's success depends on long-term financial
and infrastructural support from both the central and state governments.
While the BioE3 policy is a promising step, it is essential to create a conducive environment for long-term
capital investment and foster collaborations between the central and state governments. Without these
enabling conditions, the policy's impact may be limited. India needs to progress more in the field of
biotechnology to fully realize its potential and contribute to global advancements in this sector.
Status: India ranks among the top 12 destinations for biotechnology worldwide.
It is the 3rd largest destination for biotechnology in the Asia-Pacific region.
India's Bioeconomy reached an estimated value of USD 130 billion in 2024.
Biotechnology is recognized as a sunrise sector, playing a crucial role in India's ambition to
become a USD 5 trillion economy by 2024.
With about 3% of the global biotechnology market share, India is becoming a hub for
delivering innovative and affordable healthcare solutions.
Biotechnology Categories in India
Biopharmaceuticals: India is a leading global supplier of low-cost drugs and vaccines.
The country is also a pioneer in biosimilars, with the highest number of biosimilars approved
in the domestic market.
Bio-Agriculture: With approximately 55% of Indian land dedicated to agriculture, India
holds the 5th largest area of organic agricultural land globally.
The Bio-Agriculture sector has the potential to nearly double its BioEconomy
contribution from USD 10.5 billion to USD 20 billion by 2025.
Bio-Industrial: Biotechnology is transforming industrial processes, manufacturing, and
waste disposal across the country.
Bio IT & BioServices: India has strong capabilities in contract manufacturing, research,
and clinical trials.
The country hosts the highest number of US FDA-approved plants outside
the United States.
Government Initiatives:
100% FDI is allowed under the automatic route for greenfield pharma and for the
manufacturing of medical devices.
FDI policies are favorable, with specific routes for brownfield pharma and medical
devices.
National Biotechnology Development Strategy 2021-25 aims to make India globally
competitive in biotechnology research, innovation, translation, entrepreneurship and
industrial growth and be a USD 150 billion Bioeconomy by 2025.
The Department of Biotechnology has funded 51 Biotech-KISAN hubs to connect
farmers with scientists and institutions, focusing on sustainable agricultural practices, soil
health, irrigation, and new agri-technologies.
Under the Union Budget 2023-24, the government announced the establishment of 500
new ‘waste to wealth’ plants under the GOBARdhan scheme, with a total investment
of INR 10,000 crore.
GenomeIndia Project aims to sequence and analyze the genomes of a representative Indian
population to understand genetic diversity and its implications for public health.
The Department of Biotechnology (DBT), Government of India, announced the First
National Biotechnology Development Strategy in September 2007.
//
What are the Key Challenges Hindering the Growth of Biotechnology in India?
Regulatory Maze- Navigating the Bureaucratic Labyrinth: India's complex and often slow
regulatory environment poses a significant challenge to biotech innovation.
The approval process for genetically modified organisms (GMOs) is particularly
cumbersome, with the moratorium on Bt brinjal since 2010 serving as a prime
example.
Multiple agencies involved in regulation, including the Genetic Engineering Appraisal
Committee (GEAC) and the Review Committee on Genetic Manipulation (RCGM),
often lead to overlapping jurisdictions and delays.
Funding Famine-The Capital Crunch in Biotech: Despite government initiatives, access to
adequate funding remains a major hurdle for Indian biotech firms.
Long gestation periods and high risks associated with biotech research deter many
investors.
India's funding in 2022 for the biotechnology sector is critically low, as the entire Ministry of
Science and Technology receives only 0.05% of India's GDP as funding from the
Central Government.
Infrastructure Inadequacies-The Facilities Fallout: Despite improvements, India's biotech
infrastructure lags behind global standards in many areas.
High-end research equipment, state-of-the-art laboratories, and biocontainment facilities
are often in short supply or concentrated in a few urban centers.
The lack of reliable cold chain infrastructure poses challenges for pharmaceutical
distribution, as highlighted during the Covid-19 vaccine rollout.
While initiatives like the National Biopharma Mission aim to address these gaps, the scale
of investment required is substantial, with estimates suggesting a need for over USD 10
billion in the next decade to bring facilities up to global standards.
IP Insecurity-Protecting Innovation in a Global Market: Intellectual property protection
remains a concern for biotech innovators in India.
Patent application filing increased by 24.64%, from 66440 in 2021-22 to 80211 in
2022-23, still enforcement challenges persist.
The ongoing debate over patent protection for Covid-19 vaccines highlights the delicate
balance between innovation incentives and public health needs.
Global Gatecrashing-Competing in an Established Market: Indian biotech firms face stiff
competition from well-established global players, particularly in lucrative markets like
biopharmaceuticals.
Breaking into these markets requires not just innovative products but also significant
investments in clinical trials, regulatory compliance, and marketing.
While initiatives like the Production Linked Incentive (PLI) scheme aim to boost
competitiveness, Indian firms still have ground to cover in terms of global market
presence and brand recognition.
Talent Tug-of-War - Brain Drain and Skill Gaps: India produces a large number of biotech
graduates annually, yet faces a paradoxical shortage of skilled professionals in cutting-
edge areas.
Brain drain remains a persistent issue, with many top talents seeking opportunities abroad.
Moreover, the industry cites a significant gap between academic training and industry
needs, particularly in areas like bioinformatics, computational biology, and
bioprocess engineering. This skills mismatch hampers the sector's growth and
innovation potential.
Ethical Challenges- Navigating Moral and Social Dilemmas: Biotechnology often intersects
with complex ethical issues, creating roadblocks to research and commercialization.
The ongoing debate over genetically modified crops exemplifies this, with public
opposition stalling the introduction of GM mustard despite regulatory approvals.
Recent advancements in gene editing technologies like CRISPR have reignited
discussions on the ethical implications of human genome modification.
The lack of clear ethical guidelines and public engagement mechanisms often leads to
regulatory paralysis, hindering progress in potentially beneficial areas of research.
Conclusion
The BioE3 initiative represents a significant step towards harnessing India's biotechnology potential. For
its success, robust financial and infrastructural support is crucial. This initiative could drive
economic growth, enhance environmental sustainability, and create employment, but it requires effective
collaboration between central and state governments to overcome existing challenges. India's continued
progress in biotechnology will be pivotal for its global standing and sustainable development goals.
Q. Other than resistance to pests, what are the prospects for which genetically engineered
plants have been created? (2012)
(d) 1, 2, 3 and 4
Ans: (c)
(a) 1 only
(d) 1, 2 and 3
Ans: (d)